Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 18;172(4):281-282.
doi: 10.7326/M19-3337. Epub 2020 Jan 14.

Tenofovir Alafenamide for HIV Preexposure Prophylaxis: What Can We DISCOVER About Its True Value?

Douglas S Krakower  1 , Demetre C Daskalakis  2 , Judith Feinberg  3 , Julia L Marcus  4
Affiliations

Tenofovir Alafenamide for HIV Preexposure Prophylaxis: What Can We DISCOVER About Its True Value?

Douglas S Krakower et al. Ann Intern Med. .

Abstract

This is the prepublication, author-produced version of a manuscript accepted for publication in Annals of Internal Medicine. This version does not include post-acceptance editing and formatting. The American College of Physicians, the publisher of Annals of Internal Medicine, is not responsible for the content or presentation of the author-produced accepted version of the manuscript or any version that a third party derives from it. Readers who wish to access the definitive published version of this manuscript and any ancillary material related to this manuscript (e.g., correspondence, corrections, editorials, linked articles) should go to Annals.org or to the print issue in which the article appears. Those who cite this manuscript should cite the published version, as it is the official version of record.

PubMed Disclaimer

Comment in

References

    1. Hare CB, Coll J, Ruane P, Molina JM, Mayer KH, Jessen H, et al. The phase 3 DISCOVER study: daily F/TAF or F/TDF for HIV preexposure prophylaxis. Conference on Retroviruses and Opportunistic Infections Seattle, WA; March 4-7, 2019.
    1. Spinner CD, Brunetta J, Shalit P, Prins M, Cespedes M, Brainard D, et al. DISCOVER study for HIV pre‐exposure prophylaxis (PrEP): F/TAF has a more rapid onset and longer sustained duration of HIV protection compared with F/TDF. >IAS Conference on HIV Science Mexico City, Mexico; July 21-24, 2019.
    1. Goldstein RH, Walensky RP. Where Were the Women? Gender Parity in Clinical Trials. N Engl J Med. 2019. October 30 [Epub ahead of print] - PubMed
    1. U.S. Food and Drug Administration. FDA Briefing Information for the August 7, 2019 Meeting of the Antimicrobial Drugs Advisory Committee. https://www.fda.gov/media/129607/download. Accessed on October 8 2019.
    1. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24(11):1667–78. - PubMed